Large increase seen in insulin use, out-of-pocket costs for type 2 diabetes

June 10, 2014

Largely attributable to the widespread adoption of insulin analogs, use of insulin among patients with type 2 diabetes increased from 10 percent in 2000 to 15 percent in 2010, and out-of-pocket expenditures per prescription increased from a median of $19 to $36, according to a study in the June 11 issue of JAMA, a diabetes theme issue.

Insulin analogs are molecularly altered forms of insulin. Compared with human synthetic and animal insulin for treatment of type 2 , short-acting analogs may offer flexible dosing and convenience, long-acting analogs less nocturnal hypoglycemia, but both at greater cost, according to background information in the article.

Kasia J. Lipska, M.D., M.H.S., of the Yale University School of Medicine, New Haven, Conn., and colleagues used data from an administrative claims database of privately insured enrollees from throughout the United States (but with more representation from states in the South and Midwest) to examine trends in insulin use, out-of-pocket expenditures, and severe hypoglycemic events among privately insured U.S. with type 2 diabetes. The analysis included adults 18 years or older with at least 2 years of continuous plan enrollment between January 2000 and September 2010.

During the study period, 123,486 patients filled at least 1 prescription for insulin, comprising 9.7 percent of adults with type 2 diabetes in 2000 and 15.1 percent in 2010. Among adults who used insulin, 96.4 percent filled prescriptions for human synthetic insulin in 2000 and 14.8 percent in 2010, whereas 18.9 percent filled for insulin analogs in 2000 and 91.5 percent in 2010. Use of animal insulin was less than 1 percent during all years.

The median out-of-pocket costs per prescription for all types of insulin increased from $19 in 2000 to $36 in 2010. Severe hypoglycemic events declined slightly over the study period, but the difference was not statistically significant.

"We found a large increase in the prevalent use of analogs among privately insured patients with . The clinical value of this change is unclear," the authors conclude.

Explore further: Insulin LY2605541 tops glargine for glycemic control in T1DM

More information: DOI: 10.1001/jama.2014.6316

Related Stories

ADA: insulin-pump tx with threshold-suspend beneficial

June 24, 2013

(HealthDay)—For patients with type 1 diabetes and documented nocturnal hypoglycemia, insulin-pump therapy with a threshold-suspend feature reduces nocturnal hypoglycemia over a three-month period, according to a study published ...

Recommended for you

Do germs cause type 1 diabetes?

May 16, 2016

Germs could play a role in the development of type 1 diabetes by triggering the body's immune system to destroy the cells that produce insulin, new research suggests.

Melatonin signaling is a risk factor for type 2 diabetes

May 12, 2016

A sleeping pancreas releases less insulin, but how much insulin drops each night may differ from person to person, suggests a study published May 12, 2016 in Cell Metabolism. Up to 30 percent of the population may be predisposed ...

New gene for familial high cholesterol

May 12, 2016

New research from Denmark reveals the gene that explains one quarter of all familial hypercholesterolemia with very high blood cholesterol. Familial hypercholesterolemia is the most common genetic disorder leading to premature ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.